The Return on INVEST

JAMA

Volumn 290, Issue 21, 2003, Pages 2859-2861

  Alderman, Michael H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; RENIN; TRANDOLAPRIL; VERAPAMIL;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; EDITORIAL; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

EID: 0345530008     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.21.2859     Document Type: Editorial

References (14)

1. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
2. Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure reduction. J Hypertens. 2003;21:1055-1076.
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290: 2805-2816.
4. Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens. 2003;21:1599-1608.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981-2997.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;355:1955-1964.
7. Pabor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-time antihypertensive therapies: a metaanalysis of randomized controlled trials. Lancet. 2000;356:1949-1954.
8. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
10. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360:2-3.
11. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
12. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus-individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension. 1988;12:223-226.
13. Staessen, JA, Bianchi G. Registration of trials and protocols. Lancet. 2003; 362:1009-1010.
14. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.